Dimerix Limited (ASX:DXB)
Australia
· Delayed Price · Currency is AUD 0.405
-0.005 (-1.22%)
At close: Mar 6, 2026
Dimerix Revenue
Dimerix had revenue of 2.12M AUD in the half year ending December 31, 2025, with 1,490.79% growth. This brings the company's revenue in the last twelve months to 7.42M, up 1,219.92% year-over-year. In the fiscal year ending June 30, 2025, Dimerix had annual revenue of 5.59M with 1,271.12% growth.
Revenue (ttm)
7.42M
Revenue Growth
+1,219.92%
P/S Ratio
32.79
Revenue / Employee
494.41K
Employees
15
Market Cap
243.16M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.59M | 5.18M | 1,271.12% |
| Jun 30, 2024 | 407.47K | 370.68K | 1,007.64% |
| Jun 30, 2023 | 36.79K | -6.43M | -99.43% |
| Jun 30, 2022 | 6.46M | 2.02M | 45.58% |
| Jun 30, 2021 | 4.44M | 2.10M | 89.65% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Orthocell | 9.33M |
| Tetratherix | 2.00M |
| Starpharma Holdings | 14.58M |
| Actinogen Medical | 7.36M |
| Recce Pharmaceuticals | 974.56K |
| Racura Oncology | 3.48M |
| Botanix Pharmaceuticals | 21.92M |
| Island Pharmaceuticals | 62.85K |
Dimerix News
- 2 months ago - Dimerix Completes Enrolment In Phase 3 Trial Of DMX-200 In Focal Segmental Glomerulosclerosis - Nasdaq
- 11 months ago - Biotech Dimerix lands $940m licensing deal for kidney drug sales - The Australian Financial Review